Previously, we have shown that serial measurements of @entity1486 ( @entity1486 ) in @entity263 ( @entity263 ) can be used to calculate an average relative velocity (rva) of @entity1486 . Together, the level of @entity1486 and the rva formed a two-variable model for survival time that worked at any time during the course of @entity263 . Here, we have added serial measurements of hemoglobin and weight to test whether they improve the prior model based on @entity1486 alone. Data from two @entity5 and @entity1778 Group B studies (9181 and 9182) on @entity263 were combined to study the relationship between survival and serial measurements of @entity1486 , serum hemoglobin, and @entity1 weight. Altogether, there were 348 @entity1 who could be evaluated. We used the Cox proportional hazard model for survival time with the interval censored method to accommodate time-dependent covariates, and tests for significance were two sided. Log ( @entity1486 ), rva, log (hemoglobin), and log [weight (in kg)] were all significantly related to survival time during the course of @entity263 (P < 3.0 x 10(-5)). Together, they formed a prognostic score based upon the relative hazard. Higher values of this score implied higher probability of death as the next observed event. Serial measurements of @entity1486 , hemoglobin, and weight provide a prognostic score that can be applied continuously during the course of @entity263 . Changes in the score may provide a reproducible measure of treatment effect.

A prognostic score for @entity263 : analysis of two XXXX and @entity1778 group B studies.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity263 :: ('MESH:D011471', 'Disease') :: ['hormone-refractory prostate cancer', 'HRPC'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['Leukemia'] @entity1486 :: ('354', 'Gene') :: ['PSA', 'prostate-specific antigen']
@entity5 :: (MESH:D009369,Disease) :: ['cancer']
